Barclays raised the firm’s price target on Edwards Lifesciences (EW) to $99 from $95 and keeps an Overweight rating on the shares. The firm increased estimates post the Q3 beat.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EW: